Pirkey-Ehrhart N, Withrow S J, Straw R C, Ehrhart E J, Page R L, Hottinger H L, Hahn K A, Morrison W B, Albrecht M R, Hedlund C S
J Am Anim Hosp Assoc. 1995 Jan-Feb;31(1):65-9. doi: 10.5326/15473317-31-1-65.
Fifty-four dogs with primary tumors of the rib were evaluated. Thirty-four dogs had osteosarcomas, 15 dogs had chondrosarcomas, three dogs had hemangiosarcomas, and two dogs had fibrosarcomas. Forty-nine dogs had en bloc excision. Within the osteosarcoma group, nine animals received postoperative adjuvant chemotherapy. These animals had significantly longer median disease-free intervals (225 days) and median survival times (240 days) than dogs with osteosarcoma treated by surgery alone (median disease-free interval, 60 days; median survival, 90 days). Chondrosarcoma had a better prognosis (median disease-free interval, 1,080 days; median survival, 1,080 days) than osteosarcoma, hemangiosarcoma, or fibrosarcoma of the rib. Age, weight, sex, number of ribs resected, tumor volume, and total cisplatin dose did not influence survival nor disease-free interval.
对54只患有肋骨原发性肿瘤的犬进行了评估。34只犬患有骨肉瘤，15只犬患有软骨肉瘤，3只犬患有血管肉瘤，2只犬患有纤维肉瘤。49只犬接受了整块切除。在骨肉瘤组中，9只动物接受了术后辅助化疗。这些动物的无病生存期（225天）和中位生存时间（240天）明显长于仅接受手术治疗的骨肉瘤犬（无病生存期中位数为60天；中位生存期为90天）。软骨肉瘤的预后（无病生存期中位数为1080天；中位生存期为1080天）优于肋骨骨肉瘤、血管肉瘤或纤维肉瘤。年龄、体重、性别、切除的肋骨数量、肿瘤体积和顺铂总剂量均不影响生存期和无病间期。
